Skip to content
Sign in
SWC 2026 FinalistGrand Final: Main Stage

Nanogrow Biotech

Uruguay-Spain nanobody company pairing single-domain antibodies with local delivery for asthma, colorectal cancer, psoriasis and atopic dermatitis.

Montevideo (lab also in Spain, CEIN Pamplona/Navarre), Uruguay, Latin AmericaBiotech & life sciences, Single-domain antibodies (nanobodies)Startup World Cup Uruguay 2026 (winner; organized by IT Builders and Pegasus Tech Ventures)
Stage
SeedNo documented AI
Product
R&DNone known
Funding raised
$1.2Mdisclosed
Founded
20215 years ago
Founders
3Nicolás, Lucía…
Global score
3.0Grade DRank 126 of 151

Overview

Biotech company (CEO. Nicolás Galmarini) developing biologic treatments based on single-domain antibodies for allergic asthma, colorectal cancer, psoriasis and atopic dermatitis.

Traction

None known

No public evidence of traction found: candidates in discovery/preclinical, no clinical trials.

Market

Nanobodies (single-domain antibodies)

Biologics for asthma, psoriasis, atopic dermatitis and colorectal cancer are bought by health systems, but early-stage assets are bought by pharma via licensing. Nanobodies are a validated modality whose small size suits topical, inhaled and oral delivery, reducing systemic exposure. Value is created by clinical data milestones that trigger licensing deals. Latin American biotech relies on regional VC and European grants.

Addressable market

2025
$0.7B
2030
$1.6B
+18.3% a year

Nanobodies (single-domain antibodies): ~$0.68bn in 2025, 18.3% CAGR (ResearchAndMarkets).

Customers

Pharma and biotech licensees (dermatology, respiratory, oncology), later payers and health systems

Who signs the cheque

Pharma business development teams; investors funding milestones

Geographies

  • Uruguay
  • Spain
  • Latin America
  • Europe

Drivers

  • Industry validation of nanobodies
  • Demand for local, less systemic biologic delivery
  • Large markets in inflammatory skin and respiratory disease

Headwinds

  • Scattered preclinical pipeline
  • Far too little capital
  • Long regulatory path

ResearchAndMarkets values nanobodies at $0.58bn in 2024 and $1.58bn in 2030 (18.3% CAGR), i.e. ~$0.68bn in 2025 (calculated); range $0.6–1.8bn.

Scalability 5/10. An approved drug sells worldwide through licensing, but the preclinical-to-clinical path is long and uncertain.

Market source: researchandmarkets.com

Technology

Category

Biologics platform (nanobodies)

No documented AI

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

R&D

How it works

Single-domain antibodies are combined with local delivery formulations: topical, nebulised, injectable, oral or via DNA/RNA. Candidates are in discovery/preclinical stage.

Moat

Platform know-how in camelid nanobodies (CSO specialised) and formulations; patents not documented in the record.

Differentiation

Local delivery of small biologics versus systemic monoclonal antibodies.

Integration points

  • Drug-delivery implants and polymers
  • Clinical scoring tools for dermatology trials
  • Pharma licensing partners

Depends on

  • Preclinical data
  • GMP manufacturing
  • Regulatory approvals

Use of AI

No use of AI mentioned

Product in detail

Nanobody (sdAb) platform combined with local delivery formulations: topical, nebulized, injectable, oral or via DNA/RNA.

Business

Model
Drug development with out-licensing to pharma.
Revenue logic
Upfront and milestone payments plus royalties; no revenue yet.
Go-to-market
Partnering with pharma after preclinical/clinical proof; funded by regional VC.

Next milestones

  1. Close of the $5–10M round
  2. Lead indication selection with IND-enabling studies
  3. First pharma research collaboration

Key risks

  • Preclinical failure
  • Capital shortfall
  • Focus dilution across four indications

Opportunities

4 found in the network

Concrete moves for Nanogrow Biotech inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Co-development 3
  • Investors 1

Co-development3

An integration or joint product

Use Legit.Health AI scoring as trial endpoints in psoriasis and AD

Dermatology trials depend on severity scores that are subjective and costly to collect. Legit.Health provides CE-marked automated scoring and already partners with dermatology pharma, which could make Nanogrow's early trials cheaper and more credible to licensees.

35%confidence

Evidence from the records

  • “Computer vision and deep learning on skin images, CE-marked as a medical device, with automated severity scores”
  • “allergic asthma, colorectal cancer, psoriasis and atopic dermatitis”
  • “Novartis and Almirall”
If it works
Objective trial endpoints and a door to Legit.Health's pharma partners for licensing talks.
First step
Ask Legit.Health for its clinical-trial service terms and the scores validated for psoriasis and AD.

Test nanobody payloads in the MediChip local-release implant

Both companies bet on local delivery. MediChip is already in colorectal cancer trials, one of Nanogrow's indications; loading a nanobody could create a differentiated combination while BioSapien gains a biologic payload.

25%confidence

Evidence from the records

  • “3D-printed, biodegradable, slow-release implant that can be attached to any tissue”
  • “MediChip in clinical trials for colorectal cancer in the UAE”
  • “Nanobody (sdAb) platform combined with local delivery formulations”
If it works
A joint preclinical study and a co-development option on a local biologic oncology therapy.
First step
Organise a scientific call to check nanobody stability in BioSapien's implant materials.

Evaluate polymer depots for sustained nanobody release

Pleryon designs synthetic polymers for drug delivery and injectable biomaterials, a possible route to longer-acting nanobody formulations. Pleryon gains a biologic payload; Nanogrow gains formulation expertise.

20%confidence

Evidence from the records

  • “Proprietary platforms for designing and controlling the structure of large synthetic and modified natural polymers, for drug delivery and injectable biomaterials”
  • “topical, nebulized, injectable, oral or via DNA/RNA”
If it works
A material-transfer study toward a long-acting local formulation.
First step
Propose an MTA to test one nanobody in a Pleryon polymer.

Investors1

A fund whose thesis fits

Add PharmStars Ventures to the current round

PharmStars invests globally at pre-seed and seed in HealthTech and biotech and backed Argentine network member Cromodata, a regional warm path.

30%confidence

Evidence from the records

  • “Round in progress (closing not confirmed)”
  • “Biotech & life sciences”
If it works
Additional capital toward closing the round and pharma-network access.
First step
Ask Cromodata's founders to introduce Nanogrow to PharmStars.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

Chinese VC with no profile in our data; investor in Pleryon Therapeutics' Pre-A and Series A.

Uruguayan nanobodies — biotech platform.

15%confidence

Evidence from the records

  • “Pleryon Therapeutics”
  • “Single-domain antibodies (nanobodies)”
  • “No public evidence of traction found: candidates in discovery/preclinical, no clinical trials.”
Intro path
Founder-to-founder intro via Pleryon Therapeutics (network portfolio company of Kaitai Capital).
First step
Low priority.

Chinese VC with no profile in our data; investor in Pleryon Therapeutics' Pre-A and Series A.

Uruguayan nanobodies.

15%confidence

Evidence from the records

  • “Pleryon Therapeutics”
  • “Single-domain antibodies (nanobodies)”
  • “No public evidence of traction found: candidates in discovery/preclinical, no clinical trials.”
Intro path
Founder-to-founder intro via Pleryon Therapeutics (network portfolio company of Lapam Capital).
First step
Low priority.

Investment analysis

3.0D

Grade D

Rank 126 of 151

Disruption6.0/10
Business model1.0/10
Market3.0/10
Risk(lower is better)9.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Too early to invest.

Disruption

6/10

Nanobodies for asthma, psoriasis or cancer: a recognized modality, scattered pipeline.

Business model

1/10

Pipeline in discovery/preclinical, no revenue.

Market

3/10

Score 3/10: TAM $0.68bn → base 3; scalability 5/10 (0); no commercial presence in ≥2 countries yet (0).

Risk

9/10

Lower is better

Very high risk: scattered preclinical work with $1.2M raised.

Strengths

  • Nanobody modality validated by the industry
  • Multi-indication pipeline

Risks

  • Scattered pipeline
  • Far too little capital

Funding

$1.2M, disclosed
  1. 2024

    SeedUS$1.2M

    GridX, ATGen (El Observador)

  2. 2025-04

    Prize (most disruptive startup, South Summit Brazil)not disclosed

    South Summit

  3. 2025-2026

    Round in progress (closing not confirmed)$10M Series A targeted (Forbes Argentina); or $5M round more than 75% completed (ecosistemastartup / AEGU)

    not disclosed

  4. 2026

    Prize (Best Startup, Valencia Digital Summit 2026, against 1,560 startups from 87 countries)not disclosed

    Valencia Digital Summit

  5. 2026

    Prize (Startup World Cup Uruguay winner)qualification for the final

    IT Builders / Pegasus Tech Ventures

Amount used in the study. $1.2M seed; round in progress ($5M, >75% completed) used as upper bound.

Note. ≈ US$1.2M (2024 seed) + round in progress ($5M or $10M Series A depending on the source)

Qualification confirmed: winner of the Startup World Cup Uruguay 2026. Added the VDS 2026 Best Startup prize, a 3rd co-founder (Mariana Ferrari, ORT 2023) and the Spanish lab (Pamplona). Inconsistent founding year (2021 or 2022): left blank.

Team

  • Nicolás Galmarini

    Co-founder & CEO

    Runs Nanogrow between Uruguay and Spain; detailed background not published.

  • Lucía Vanrell, PhD

    Co-founder & CSO

    PhD in biotechnology specializing in nanobodies (camelid antibodies); Emprendedora Navarra 2025 (AMEDNA).

  • Mariana Ferrari

    Co-founder (cited in 2023)

    Deputy academic coordinator in biotechnology at Universidad ORT Uruguay; cited among the founders of Nanogrow (ORT, 2023).

Sources

Regional final
Startup World Cup Uruguay 2026 (winner; organized by IT Builders and Pegasus Tech Ventures)
Identification confidence
medium
Founding year: 2021 (medium confidence)
Founded in 2021 by Nicolás Galmarini and Lucía Vanrell (Uruguay XXI, Ecosistema Startup); a LinkedIn post says 2022. uruguayxxi.gub.uy
  1. 1nanogrowbiotech.com/
  2. 2ecosistemastartup.com/nanogrow-gana-la-startup-world-cup-uruguay-y-va-a-san-franc
  3. 3ecosistemastartup.com/?p=121292
  4. 4ort.edu.uy/en/news/emprendimiento-de-biotecnologia-seleccionado-para-r

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet